-
Mashup Score: 9
Genicular nerve block (GNB) has emerged as a promising intervention for knee osteoarthritis (KOA), yet its comparative efficacy remains incompletely understood. The purpose of this review was to as…
Source: www.tandfonline.comCategories: General Medicine NewsTweet
-
Mashup Score: 1Global burden of osteoarthritis attributable to high body mass index, 1990‐2021: insights from the Global Burden of Disease study 2021 - 15 hour(s) ago
Objective This study quantifies the global burden of osteoarthritis (OA) attributable to high body mass index (BMI) from 1990 to 2021 using the Global Burden of Disease (GBD) 2021 data. Methods Ut…
Categories: General Medicine NewsTweet-
From 1990 to 2021, the global burden of OA from high BMI increased markedly. YLD (years lived w/ disability) rates of OA attributable to high BMI increased from 34 to 50.6 per 100,000 - higher in females, correlated w/ Socio-demographic Index levels https://t.co/RjTJFNEbYm https://t.co/tIqmn9eLQ6
-
-
Mashup Score: 3A robust machine learning approach to predicting remission and stratifying risk in rheumatoid arthritis patients treated with bDMARDs - 1 day(s) ago
Scientific Reports – A robust machine learning approach to predicting remission and stratifying risk in rheumatoid arthritis patients treated with bDMARDs
Source: www.nature.comCategories: General Medicine NewsTweet-
1,494 Ehrlangen RA pts - machine learning used baseline variables to predict remission at 6 mos. Best/most predictive results w/ AdaBoost modelingdemonstrated strongest accuracy of 85.71% (based on DAS28, Age, VAS and swollen joints. https://t.co/h9UgUKUFo4
-
-
Mashup Score: 13Evaluation of clinical biomarkers for differential diagnosis of intravascular lymphoma and Still’s disease - 1 day(s) ago
Scientific Reports – Evaluation of clinical biomarkers for differential diagnosis of intravascular lymphoma and Still’s disease
Source: www.nature.comCategories: General Medicine NewsTweet-
Japanese cohort study compared 12 pts w/ Stills Dz or intravascular lymphoma. Stills pt had significantly higher ferritin and IL-18 levels and IVL pts had significantly higher sIL-2R levels. https://t.co/Ecd6vNJTc4 https://t.co/KdEcpDeskA
-
-
Mashup Score: 29
TikTok points researcher toward signal of benefit
Source: www.medpagetoday.comCategories: General Medicine NewsTweet-
#EULAR2025 TriNetX database study indicated that fibromyalgia patients who used glucagon-like peptide-1 (GLP-1) receptor agonist drugs were less likely to use opioids and to report pain, fatigue, and malaise compared with propensity-matched non-users https://t.co/ftm93VwW65 https://t.co/GpC7QliKXH
-
-
Mashup Score: 2Patient Phenotypes Within the Clinical Program of an IL-23 Inhibitor for PsA | RheumNow - 18 day(s) ago
Watch rheumatologist Dr. Alexis Ogdie and rheumatologist and dermatologist Dr. Saakshi Khattri discuss a new analysis of patient phenotypes in PsA from clinical trials of an IL-23 inhibitor. In this conversation, they discuss disease activity differences between clinical trial populations and real-world patients, efficacy of an IL-23 inhibitor in a bionaïve, moderate PsA phenotype, and the IL-23 inhibitor’s potential role in managing patients with PsA.
Source: rheumnow.comCategories: General Medicine NewsTweet-
Patient Phenotypes in PsA Clinical Trials of an IL-23 Inhibitor Dr. Alexis Ogdie and Dr. Saakshi Khattri discuss a new PsA phenotype analysis and potential clinical applications. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/kJeSteVoxE https://t.co/CBV09mzFUN
-
-
Mashup Score: 28
TikTok points researcher toward signal of benefit
Source: www.medpagetoday.comCategories: General Medicine NewsTweet-
#EULAR2025 TriNetX database study indicated that fibromyalgia patients who used glucagon-like peptide-1 (GLP-1) receptor agonist drugs were less likely to use opioids and to report pain, fatigue, and malaise compared with propensity-matched non-users https://t.co/ftm93VwW65 https://t.co/GpC7QliKXH
-
-
Mashup Score: 16Dr. John Cush - 20 day(s) ago
EULAR 2025 – SpA Panel Discussion
Source: twitter.comCategories: General Medicine NewsTweet-
EULAR 2025 – SpA Panel Discussion https://t.co/cKFUt5bW1N
-
-
Mashup Score: 6Long-term maintenance of response of an IL-23i in PsA | RheumNow - 21 day(s) agoSource: rheumnow.comCategories: General Medicine News, RheumatologyTweet
-
NEW POSTER: 4-Year maintenance of an IL-23i response in PsA View maintenance of ACR20/50/70, MDA, PASI90 responses, and meaningful pain reduction through ~4 years in the KEEPsAKE 1 and 2 studies. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/9DZZzsJFJ5 https://t.co/KEKM6Qe1EG
-
-
Mashup Score: 2Patient Phenotypes Within the Clinical Program of an IL-23 Inhibitor for PsA | RheumNow - 21 day(s) ago
Watch rheumatologist Dr. Alexis Ogdie and rheumatologist and dermatologist Dr. Saakshi Khattri discuss a new analysis of patient phenotypes in PsA from clinical trials of an IL-23 inhibitor. In this conversation, they discuss disease activity differences between clinical trial populations and real-world patients, efficacy of an IL-23 inhibitor in a bionaïve, moderate PsA phenotype, and the IL-23 inhibitor’s potential role in managing patients with PsA.
Source: rheumnow.comCategories: General Medicine NewsTweet-
Patient Phenotypes in PsA Clinical Trials of an IL-23 Inhibitor Dr. Alexis Ogdie and Dr. Saakshi Khattri discuss a new PsA phenotype analysis and potential clinical applications. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/kJeSteVoxE https://t.co/CBV09mzFUN
-
Genicular nerve block (GNB) is effective intervention for Knee OA. Metanalysis of 6 RCTs & 420 KOA pts. GNB significantly reduced pain & improved function (p<0.003), w/ significant relief as early as 2wks and function by 12 weeks. https://t.co/NMtiQPICpw https://t.co/gVJ0TyuY01